AstraZeneca PLC (AZN)

NYSE: AZN · Real-Time Price · USD

166.08

-0.06 (-0.04%)

At close: Sep 18, 2026, 4:00 PM EDT

167.96

+1.88 (1.13%)

After-hours: Sep 18, 2026, 7:57 PM EDT

Market Cap	259.31B +7.8%
Revenue (ttm)	61.37B +8.6%
Net Income	10.45B +25.9%
EPS	6.68 +25.8%
Shares Out	1.55B
PE Ratio	24.82
Forward PE	15.33
Dividend	$3.23 (1.95%)
Ex-Dividend Date	Aug 7, 2026

Volume	3,060,398
Open	167.15
Previous Close	166.14
Day's Range	165.54 - 167.83
52-Week Range	146.10 - 212.71
Beta	0.21
Analysts	Strong Buy
Price Target	212.90 (+28.19%)
Earnings Date	Oct 30, 2026

About AZN

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company offers Imjudo, Datroway, Iressa, Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Crestor, Andexxa, Onglyza, Symlin, XIGDUO XR, Atacand, Atacand HCT, Atacand Plus, Farxiga/Forxiga, Plendil, Modip, Splendil, Munobal, Flodil, Tenormin, Tenormine, Prenormine, Atenol, Zestril, Brilinta/Brilique, Komboglyze, Qtern, Wainua, Byetta, Lokelma, Seloken ZOK, Topr... [Read more]

Industry Drug Manufacturers - General

Sector Healthcare

IPO Date May 12, 1993

Employees 95,100

Stock Exchange NYSE

Ticker Symbol AZN

Website https://www.astrazeneca.com

Full Company Profile

Financial Performance

In 2025, AstraZeneca's revenue was $58.74 billion, an increase of 8.63% compared to the previous year's $54.07 billion. Earnings were $10.23 billion, an increase of 45.34%.

Financial Statements

Analyst Summary

According to 11 analysts, the average rating for AZN stock is "Strong Buy." The 12-month stock price target is $212.9, which is an increase of 28.19% from the latest price.

Price Target

$212.9

(28.19% upside)

Analyst Consensus: Strong Buy

Stock Forecasts